Management of Patients With Refractory Angina: Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines

Canadian Journal of Cardiology

Volumn 28, Issue 2 SUPPL., 2012, Pages

  McGillion, Michael ^a   Arthur, Heather M ^b   Cook, Allison ^c   Carroll, Sandra L ^b   Victor, J Charles ^a   L'Allier, Philippe L ^d   Jolicoeur, E Marc ^d   Svorkdal, Nelson ^e   Niznick, Joel ^f   Teoh, Kevin ^g   Cosman, Tammy ^c   Sessle, Barry ^a   Watt Watson, Judy ^a   Clark, Alexander ^h   Taenzer, Paul ⁱ   Coyte, Peter ^a   Malysh, Louise ^j   Galte, Carol ^k   Stone, James ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Ottawa Cardiovascular Centre   (Canada)

^g SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j ST PAUL S HOSPITAL   (Canada)

^k FRASER HEALTH AUTHORITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; IVABRADINE; NICORANDIL; RANOLAZINE; TRIMETAZIDINE;

ANGINA PECTORIS; ARTICLE; CANADA; CLINICAL PRACTICE; COGNITIVE THERAPY; COUNTERPULSATION; DRUG APPROVAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENHANCED EXTERNAL COUNTER PULSATION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS MYOCARDIAL LASER REVASCULARIZATION; PRACTICE GUIDELINE; REFRACTORY ANGINA; SELF CARE; SPINAL CORD STIMULATION; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ANGINA PECTORIS; CANADA; CARDIOVASCULAR AGENTS; DISEASE MANAGEMENT; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL REVASCULARIZATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PAIN, INTRACTABLE; PATIENT CARE TEAM; QUALITY INDICATORS, HEALTH CARE; RECURRENCE; SAFETY MANAGEMENT; SELF CARE; SICKNESS IMPACT PROFILE; SOCIETIES, MEDICAL; STRESS, PSYCHOLOGICAL;

EID: 84858313344     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.07.007     Document Type: Article

References (182)

1. Mannheimer C., Camici P., Chester M.R., et al. The problem of chronic refractory angina report from the ESC joint study group on the treatment of refractory angina. Eur Heart J 2002, 23:355-370.
2. Bhatt A.B., Stone P.H. Current strategies for the prevention of angina in patients with stable coronary artery disease. Curr Opin Cardiol 2006, 21:492-502.
3. Henry T.D. A new option for the "no-option" patient with refractory angina?. Catheter Cardiovasc Interv 2009, 74:395-397.
4. Brorsson B., Bernstein S.J., Brook R.H., Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 2002, 87:140-145.
5. McGillion M., Watt-Watson J., LeFort S., Stevens B. Positive shifts in the perceived meaning of cardiac pain following a psychoeducation program for chronic stable angina. Can J Nurs Res 2007, 39:48-65.
6. Erixson G., Jerlock M., Dahlberg K. Experiences of living with angina pectoris. Nurs Sci Res Nordic Countries 1997, 17:34-38.
7. McGillion M.H., Watt-Watson J.H., Kim J., Graham A. Learning by heart: a focused group study to determine the self-management learning needs of chronic stable angina patients. Can J Cardiovasc Nurs 2004, 14:12-22.
8. Chow C.M., Donovan L., Manuel D., et al. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005, 21:1265-1271.
9. Thadani U. Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris. Coron Artery Dis 2004, 15(suppl 1):S1-S4.
10. McGillion M., Arthur H., Andrell P., Watt-Watson J. Self-management training in refractory angina. BMJ 2008, 336:338-339.
11. Genius S.J. The proliferation of clinical practice guidelines: professional development or medicine-by-numbers?. J Am Board Fam Pract 2005, 18:419-425.
12. Manuel D.G., Leung M., Nguyen K., et al. Burden of cardiovascular disease in Canada. Can J Cardiol 2003, 19:997-1004.
13. Stewart S., Murphy N., Walker A., McGuire A., McMurray J.J.V. The current cost of angina pectoris to the national health service in the UK. Heart 2003, 89:848-853.
14. McGillion M., Croxford R., Watt-Watson J., et al. Cost of illness for chronic stable angina patients enrolled in a self-management education trial. Can J Cardiol 2008, 24:759-764.
15. McGillion M., L'Allier P.L., Arthur H.M., et al. Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement. Can J Cardiol 2009, 25:399-401.
16. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
17. Jaeschke R., Guyatt G.H., Dellinger P., et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008, 337:a744.
18. Schünemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106-1110.
19. Guyatt G., Gutterman D., Baumann M.H., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006, 129:174-181.
20. Kones R. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag 2010, 6:749-774.
21. Crea F., Gaspardone A. New look to an old symptom: angina pectoris. Circulation 1997, 96:3766-3773.
22. Zahner M.R., Li D.P., Chen S.R., Pan H.L. Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 2003, 551(Pt 2):515-523.
23. Ambrose J. Myocardial ischemia and infarction. J Am Coll Cardiol 2006, 47(11 suppl D):D13-D17.
24. Sylven C., Eriksson C. Thorax. Wall and Melzack's Textbook of Pain 2006, 737-751. Elsevier Churchill Livingstone, Philadelphia. 5th Ed. S.B. MacMahon, M. Koltzenburg (Eds.).
25. Fox K., Garcia M.A., Ardissino D., et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341-1381.
26. Foreman R.D. Mechanisms of cardiac pain. Annu Rev Physiol 1999, 61:143-167.
27. Klein J., Chao S., Berman D., Rozanski A. Is 'silent' myocardial ischemia really as severe as symptomatic ischemia?. The analytical effect of patient selection biases. Circulation 1994, 89:1958-1966.
28. Foreman R.D., Qin C. Neuromodulation of cardiac pain and cerebral vasculature: neural mechanisms. Cleve Clin J Med 2009, 76(suppl 2):S75-S79.
29. Procacci P., Zoppi M., Maresca Heart, vascular and haemopathic pain. Textbook of Pain 1999, 621-639. Churchill Livingstone, Edinburgh. 4th Ed.
30. Melzack R., Wall P.D. Pain mechanisms: a new theory. Science 1965, 150:971-979.
31. Wolf C.J., Salter M. Plasticity and pain. Wall and Melzack's Textbook of Pain 2006, 91-105. Elsevier Churchill Livingstone, Philadelphia. 5th Ed. S.B. MacMahon, M. Koltzenburg (Eds.).
32. Basbaum A., Bushnell M.C., Devor M. Pain: basic mechanisms. Pain 2008. An Updated Review Refresher Course Syllabus 2008, 3-10. IASP Press, Glasgow. J. Castro-Lopes, S. Raja, M. Schmelz (Eds.).
33. Guyatt G.H., Oxman A.D., Kunz R., et al. Going from evidence to recommendations. BMJ 2008, 336:1049-1051.
34. Fraker T.D., Fihn S.D., Gibbons R.J., et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007, 116:2762-2772.
35. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation 2003, 107:149-158.
36. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2008, Saunders/Elsevier, Philadelphia. 8th Ed. P. Libby, E. Braunwald (Eds.).
37. Chest Pain: Advanced Assessment and Management Skills 2007, Blackwell Publishing, Malden, MA. J.W. Albarran, J. Tagney (Eds.).
38. Kones R. Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag 2010, 6:635-656.
39. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002, 18:371-379.
40. Handbook of Pain Assessment 2010, Guilford Press, New York. 3rd Ed. D.C. Turk, R. Melzack (Eds.).
41. Melzack R., Katz J. Pain assessment in adult patients. Wall and Melzack's Textbook of Pain 2006, 291-304. Elsevier Churchill Livingstone, Philadelphia. 5th ed. S.B. MacMahon, M. Koltzenburg (Eds.).
42. Smith J.A., Dunning J.J., Parry A.J., Large S.R., Wallwork J. Transmyocardial laser revascularization. J Card Surg 1995, 10:569-572.
43. Allen K.B., Dowling R.D., Fudge T.L., et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999, 341:1029-1036.
44. Burkhoff D., Wesley M.N., Resar J.R., Lansing A.M. Factors correlating with risk of mortality after transmyocardial revascularization. J Am Coll Cardiol 1999, 34:55-61.
45. Aaberge L., Nordstrand K., Dragsund M., et al. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. J Am Coll Cardiol 2000, 35:1170-1177.
46. Frazier O.H., March R.J., Horvath K.A. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999, 341:1021-1028.
47. Schofield P., Sharples L., Caine N., et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999, 353:519-524.
48. van der Sloot J.A., Huikeshoven M., Tukkie R., et al. Transmyocardial revascularization using an XeCl excimer laser: results of a randomized trial. Ann Thorac Surg 2004, 78:875-881. [discussion 881-2].
49. Briones E., Lacalle J.R., Marin I. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev 2009, CD003712.
50. Burkhoff D., Schmidt S., Schulman S.P., et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC investigators. Angina treatments-lasers and normal therapies in comparison. Lancet 1999, 354:885-890.
51. Jones J.W., Schmidt S.E., Richman B.W., et al. Holmium: YAG laser transmyocardial revascularization relieves angina and improves functional status. Ann Thorac Surg 1999, 67:1596-1602.
52. Oesterle S.N. Laser percutaneous myocardial revascularization. Am J Cardiol 1999, 83:46B-52B.
53. Spertus J.A., Winder J.A., Dewhurst T.A., et al. Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995, 25:333-341.
54. McGillion M., Cook A., Victor J.C., et al. Effectiveness of percutaneous laser revascularization therapy for refractory angina. Vasc Health Risk Manag 2010, 6:735-747.
55. Oesterle S.N., Sanborn T.A., Ali N., et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential class improvement from intramyocardial channels. Lancet 2000, 356:1705-1710.
56. Salem M., Rotevatn S., Stavnes S., et al. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. Am J Cardiol 2004, 93:1086-1091.
57. 2 laser. Ann Thorac Surg 1997, 63:1275-1283.
58. Gassler N., Wintzer H.O., Stubbe H.M., Wullbrand A., Helmchen U. Transmyocardial laser revascularization. histological features in human nonresponder myocardium. Circulation 1997, 95:371-375.
59. Mueller X.M., Tevaearai H.H., Genton C.Y., Bettex D., von Segesser L.K. Transmyocardial laser revascularisation in acutely ischaemic myocardium. Eur J Cardiothorac Surg 1998, 13:170-175.
60. Mirhoseini M., Fisher J.C., Cayton M. Myocardial revascularization by laser: a clinical report. Lasers Surg Med 1983, 3:241-245.
61. Mukherjee D., Ellis S.G. New options for untreatable coronary artery disease: angiogenesis and laser revascularization. Cleve Clin J Med 2000, 67:577-583.
62. Rimoldi O., Burns S.M., Rosen S.D., et al. Measurement of myocardial blood flow with positron emission tomography before and after transmyocardial laser revascularization. Circulation 1999, 100(suppl 19):134-138.
63. Burns S.M., Brown S., White C.A., et al. Quantitative analysis of myocardial perfusion changes with transmyocardial laser revascularization. Am J Cardiol 2001, 87:861-867.
64. Guzzetti S., Colombo A., Piccaluga E., et al. Absence of clinical signs of cardiac denervation after percutaneous myocardial laser revascularization. Int J Cardiol 2003, 91:129-135.
65. Al-Sheikh T., Allen K.B., Straka S.P., et al. Cardiac sympathetic denervation after transmyocardial laser revascularization. Circulation 1999, 100:135-140.
66. Myers J., Oesterle S.N., Jones J., Burkhoff D. Do transmyocardial and percutaneous laser revascularization induce silent ischemia?. An assessment by exercise testing. Am Heart J 2002, 143:1052-1057.
67. Beek J.F., van der Sloot J.A., Huikeshoven M., et al. Cardiac denervation after clinical transmyocardial laser revascularization: short-term and long-term iodine 123-labeled meta-iodobenzylguanide scintigraphic evidence. J Thorac Cardiovasc Surg 2004, 127:517-524.
68. Whitlow P.L., DeMaio S.J., Perin E.C., et al. One-year results of percutaneous myocardial revascularization for refractory angina pectoris. Am J Cardiol 2003, 91:1342-1346.
69. Gray T.J., Burns S.M., Clarke S.C., et al. Percutaneous myocardial laser revascularization in patients with refractory angina pectoris. Am J Cardiol 2003, 91:661-666.
70. Salem M., Rotevatn S., Nordrehaug J.E. Long-term results following percutaneous myocardial laser therapy. Coron Artery Dis 2006, 17:385-390.
71. McNab D., Khan S.N. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial [reply]. Eur Heart J 2006, 27:1632.
72. Leon M.B., Kornowski R., Downey W.E., et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005, 46:1812-1819.
73. Stone G.W., Teirstein P.S., Rubenstein R., et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol 2002, 39:1581-1587.
74. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, L Erlbaum Associates, Hillsdale, NJ. 2nd Ed.
75. Juni P., Altman D.G., Egger M. Assessing the quality of controlled clinical trials. Br Med J 2001, 323:42.
76. Ekre O., Eliasson T., Norrsell H., Wahrborg P., Mannheimer C. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J 2002, 23:1938-1945.
77. DeJongste M.J.L. Efficacy, safety and mechanisms of spinal cord stimulation used as an additional therapy for patients suffering from chronic refractory angina pectoris. Neuromodulation 1999, 2:188-192.
78. TenVaarwerk I.A.M., Jessurun G.A.J., DeJongste M.J.L., et al. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. Heart 1999, 82:82-88.
79. Eliasson T., Augustinsson L.E., Mannheimer C. Spinal cord stimulation in severe angina pectoris-presentation of current studies, indications and clinical experience. Pain 1996, 65:169-179.
80. Svorkdal N. Treatment of inoperable coronary disease and refractory angina: spinal stimulators, epidurals, gene therapy, transmyocardial laser, and counterpulsation. Semin Cardiothorac Vasc Anesth 2004, 8:43-58.
81. Taylor R.S., De Vries J., Buscher E., DeJongste M.J.L. Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials. BMC Cardiovasc Disord 2009, 9:13.
82. Di Pede F., Zuin G., Giada F., et al. Long-term effects of spinal cord stimulation on myocardial ischemia and heart rate variability: results of a 48-hour ambulatory electrocardiographic monitoring. Ital Heart J 2001, 2:690-695.
83. Eddicks S., Maier-Hauff K., Schenk M., et al. Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study. Heart 2007, 93:585-590.
84. Jessurun G.A.J., Dejongste M.J.L., Hautvast R.W.M., et al. Clinical follow-up after cessation of chronic electrical neuromodulation in patients with severe coronary artery disease: A prospective randomized controlled study on putative involvement of sympathetic activity. Pacing Clin Electrophysiol 1999, 22:1432-1439.
85. Hautvast R.W., DeJongste M.J., Staal M.J., van Gilst W.H., Lie K.I. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J 1998, 136:1114-1120.
86. DeJongste M.J., Hautvast R.W., Hillege H.L., Lie K.L. Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris: a prospective, randomized clinical study. Working Group on Neurocardiology. J Am Coll Cardiol 1994, 23:1592-1597.
87. Mannheimer C., Eliasson T., Augustinsson L., et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 1998, 97:1157-1163.
88. McNab D., Khan S.N., Sharples L.D., et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: The SPiRiT trial. Eur Heart J 2006, 27:1048-1053.
89. Di Pede F., Lanza G.A., Zuin G., et al. Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am J Cardiol 2003, 91:951-955.
90. Norrsell H., Pilhall M., Eliasson T., Mannheimer C. Effects of spinal cord stimulation and coronary artery bypass grafting on myocardial ischemia and heart rate variability: further results from the ESBY study. Cardiology 2000, 94:12-18.
91. Moore R., Groves D., Hammond C., Leach A., Chester M.R. Temporary sympathectomy in the treatment of chronic refractory angina. J Pain Symptom Manage 2005, 30:183-191.
92. Chester M., Hammond C., Leach A. Long-term benefits of stellate ganglion block in severe chronic refractory angina. Pain 2000, 87:103-105.
93. Hammond C., Collins A., Leach A.A., Chester M.R. Spinal cord stimulation for the treatment of refractory angina. Br J Cardiol 2000, 7:473. 74, 476-77.
94. Blomberg S.G., Svorkdal N. Thoracic epidural anaesthesia for treatment of refractory angina pectoris. Baillieres Clin Anaesthesiol 1999, 13:83-99.
95. Blomberg S.G. Long-term home self-treatment with high thoracic epidural anesthesia in patients with severe coronary artery disease. Anesth Analg 1994, 79:413-421.
96. Richter A., Cederholm I., Jonasson L., et al. Effect of thoracic epidural analgesia on refractory angina pectoris: long-term home self-treatment. J Cardiothorac Vasc Anesth 2002, 16:679-684.
97. Gramling-Babb P. High thoracic epidural analgesia for relief of coronary ischemia syndrome without cardiac surgery. Tech Reg Anesth Pain Manag 2008, 12:80-86.
98. Gramling-Babb P.M., Zile M.R., Reeves S.T. Preliminary report on high thoracic epidural analgesia: relationship between its therapeutic effects and myocardial blood flow as assessed by stress thallium distribution. J Cardiothorac Vasc Anesth 2000, 14:657-661.
99. Drott C. Results of endoscopic thoracic sympathectomy (ETS) on hyperhydrosis, facial blushing, angina pectoris, vascular disorders and pain syndromes of the hand and arm. Clin Auton Res 2003, 13(suppl 1):I26-I30.
100. Wettervik C., Claes G., Drott C., et al. Endoscopic transthoracic sympathectomy for severe angina. Lancet 1995, 345:97-98.
101. Stritsky M., Dobias M., Demes R., et al. Endoscopic thoracic sympathectomy; its effect in the treatment of refractory angina. Interact Cardiovasc Thorac Surg 2006, 5:464-468.
102. Breivik H., Cousins M.J., Lofstrom J.B. Sympathetic neural blockade of upper and lower extremity. Neural Blockade in Clinical Anesthesia and Pain 1998, 411-447. Lippincott-Raven, New York. 3rd Ed. M.J. Cousins, P.O. Bridenbaugh (Eds.).
103. Loh P.H., Cleland J.G., Louis A.A., et al. Enhanced external counterpulsation in the treatment of chronic refractory angina: A long-term follow-up outcome from the international enhanced external counterpulsation patient registry. Clin Cardiol 2008, 31:159-164.
104. Soran O. Treatment options for refractory angina pectoris: enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med 2009, 11:54-60.
105. Arora R.R., Chou T.M., Jain D., et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999, 33:1833-1840.
106. Michaels A.D., Accad M.P., Thomas A., Grossman W. Left ventricular systolic unloading and augmentation of intracoronary pressure and doppler flow during enhanced external counterpulsation. Circulation 2002, 106:1237-1242.
107. Masuda D., Nohara R., Hirai T., et al. Enhanced external counter-pulsation improved myocardial perfusion and coronary flow reserve in patients with chronic stable angina; evaluation by(13)N-ammonia positron emission tomography. Eur Heart J 2001, 22:1451-1458.
108. Werner D., Schneider M., Weise M., Nonnast-Daniel B., Daniel W.G. Pneumatic external counterpulsation: a new noninvasive method to improve organ perfusion. Am J Cardiol 1999, 84:950-952.
109. Barsheshet A., Hod H., Shechter M., et al. The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris. Cardiology 2008, 110:160-166.
110. Bonetti P.O., Barsness G.W., Keelan P.C., et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003, 41:1761-1768.
111. Shechter M., Matetzky S., Feinberg M.S., et al. External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol 2003, 42:2090-2095.
112. Braith R.W., Conti C.R., Nichols W.W., et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina. A randomized sham-controlled study. Circulation 2010, 122:1612-1620.
113. Amin F., Al Hajeri A., Civelek B., Fedorowicz Z., Manzer B.M. Enhanced external counterpulsation for chronic angina pectoris. Cochrane Database Syst Rev 2008, CD007219.
114. Arora R.R., Chou T.M., Jain D., et al. Effects of enhanced external counterpulsation on health-related quality of life continue 12 months after treatment: a substudy of the multicenter study of enhanced external counterpulsation. J Invest Med 2002, 50:25-32.
115. Kumar A., Aronow W.S., Vadnerkar A., et al. Effect of enhanced external counterpulsation on clinical symptoms, quality of life, 6-minute walking distance, and echocardiographic measurements of left ventricular systolic and diastolic function after 35 days of treatment and at 1-year follow up in 47 patients with chronic refractory angina pectoris. Am J Ther 2009, 16:116-118.
116. Michaels A.D., Raisinghani A., Soran O., et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: A multicenter radionuclide study. Am Heart J 2005, 150:1066-1073.
117. Springer S., Fife A., Lawson W., et al. Psychosocial effects of enhanced external counterpulsation in the angina patient: a second study. Psychosomatics 2001, 42:124-132.
118. Tartaglia J., Stenerson J., Charney R., et al. Exercise capability and myocardial perfusion in chronic angina patients treated with enhanced external counterpulsation. Clin Cardiol 2003, 26:287-290.
119. Werner D., Kropp J., Schellong S., et al. Practicability and limitations of enhanced external counterpulsation as an additional treatment for angina. Clin Cardiol 2003, 26:525-529.
120. Pettersson T., Bondesson S., Cojocaru D., et al. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 2006, 6:28.
121. Loh P.H., Louis A.A., Windram J., et al. The immediate and long-term outcome of enhanced external counterpulsation in treatment of chronic stable refractory angina. J Intern Med 2006, 259:276-284.
122. Werner D., Kropp J., Schellong S., et al. Practicability and limitations of enhanced external counterpulsation as an additional treatment for angina. Clin Cardiol 2003, 26:525-529.
123. Loh P.H., Louis A.A., Windram J., et al. The immediate and long-term outcome of enhanced external counterpulsation in treatment of chronic stable refractory angina. J Intern Med 2006, 259:276-284.
124. Barlow J.H., Shaw K.L., Harrison K. Consulting the 'experts': children's and parents' perceptions of psycho-educational interventions in the context of juvenile chronic arthritis. Health Educ Res 1999, 14:597-610.
125. McGillion M.H., Watt-Watson J., Stevens B., et al. Randomized controlled trial of a psychoeducation program for the self-management of chronic cardiac pain. J Pain Symptom Manage 2008, 36:126-140.
126. Barlow J.H., Sturt J., Hearnshaw H. Self-management interventions for people with chronic conditions in primary care: examples from arthritis, asthma and diabetes. Health Educ J 2002, 61:365-378.
127. Holman H., Lorig K. Patient self-management: a key to effectiveness and efficiency in care of chronic disease. Public Health Rep 2004, 119:239-243.
128. Bodenheimer T., Lorig K., Holman H., Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002, 288:2469-2475.
129. McGillion M.H., Watt-Watson J.H., Kim J., Graham A. Learning by heart: a focused group study to determine the self-management learning needs of chronic stable angina patients. Can J Cardiovasc Nurs 2004, 14:12-22.
130. Holman H., Lorig K. Patients as partners in managing chronic disease. Partnership is a prerequisite for effective and efficient health care. BMJ 2000, 320:526-527.
131. LeFort S.M., Gray-Donald K., Rowat K.M., Jeans M.E. Randomized controlled trial of a community-based psychoeducation program for the self-management of chronic pain. Pain 1998, 74:297-306.
132. McGillion M., Arthur H., Victor J.C., Watt-Watson J., Cosman T. Effectiveness of psychoeducational interventions for improving symptoms, health-related quality of life, and psychological well being in patients with stable angina. Curr Cardiol Rev 2008, 4:1-11.
133. Bundy C., Carroll D., Wallace L., Nagle R. Psychological treatment of chronic stable angina pectoris. Psychol Health 1994, 10:69-77.
134. Gallacher J.E.J., Hopkinson C.A., Bennett M.L., Burr M.L., Elwood P.C. Effect of stress management on angina. Psychol Health 1997, 12:523-532.
135. Lewin R.J., Furze G., Robinson J., et al. A randomised controlled trial of a self-management plan for patients with newly diagnosed angina. Br J Gen Pract 2002, 52:194-196. 199-201.
136. Payne T.J., Johnson C.A., Penzien D.B., et al. Chest pain self-management training for patients with coronary artery disease. J Psychosom Res 1994, 38:409-418.
137. Lewin B., Cay E., Todd I., et al. The angina management programme: a rehabilitation treatment. Br J Cardiol 1995, 2:221-226.
138. Mellin V., Isabelle M., Oudot A., et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005, 26:1544.
139. Farquharson C.A.J., Butler R., Hill A., Belch J.J.F., Struthers A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
140. Noman A., Ang D.S., Ogston S., Lang C.C., Struthers A.D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010, 375:2161-2167.
141. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462-2472.
142. Chaitman B.R., Pepine C.J., Parker J.O., et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
143. Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006, 48:566-575.
144. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116:1647-1652.
145. Koren M.J., Crager M.R., Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The ranolazine open label experience (ROLE). J Am Coll Cardiol 2007, 49:1027-1034.
146. Harpey C., Clauser P., Labrid C., Fryria J., Poirier J. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drugs Rev 1989, 6:292-312.
147. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimeetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3-ketoactly coenzyme A thiolase. Circ Res 2000, 86:580-588.
148. Lazar E.J., Frishman W.H. Profile of an ideal antianginal agent. Drugs 1989, 38(suppl 2):1S-8S.
149. Ciapponi A., Pizarro R., Harrison J. Trimetazadine for stable angina. Cochrane Database Syst Rev 2005, CD003614.
150. Szwed H., Sadowski Z., Elikowski W., et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001, 22:2267-2274.
151. Treese N., Erbel R., Meyer J. Acute hemodynamic effects of nicorandil in coronary artery disease. J Cardiovasc Pharmacol 1992, 20(suppl 3):S52-S56.
152. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992, 20(suppl 3):S74-S81.
153. Meeter K., Kelder J.C., Tijssen J.G.P., et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: A long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992, 20(suppl 3):S59-S66.
154. Hughes L.O., Rose E.L., Lahiri A., Raftery E.B. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990, 66:679-682.
155. Di Somma S., Liguori V., Petitto M., et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993, 7:119-123.
156. Ulvenstam G., Diderholm E., Frithz G., et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992, 20(suppl 3):S67-S73.
157. Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993, 14(suppl B):30-34.
158. Zhu W.L., Shan Y.D., Guo J.X., et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in china. Circ J 2007, 71:826-833.
159. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial [erratum in 2002;360:806]. Lancet 2002, 359:1269-1275. IONA Study Group.
160. Walker A., McMurray J., Stewart S., et al. Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart 2006, 92:619-624.
161. f inhibitor: efficacy and safety in stable angina. Eur Heart J 2003, 5(suppl G):G36-G45.
162. Fox K. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina. Expert Opin Pharmacother 2006, 7:1211-1220.
163. Camm A.J., Lau C.P. Electrophysiological effect of a single intravenous administration of ivabradine (S16257) in adult patients with normal electrophysiology. Drugs R D 2003, 4:83-89.
164. Vilaine J.P., Bidourd J.P., Lesage L., Reure H., Peglion J.L. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in excercise induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003, 42:688-696.
165. Joannides R., Moore N., Iacob M., et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2006, 61:127-137.
166. Manz M., Reuter M., Lauck G., Omran H., Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003, 100:149-155.
167. f inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107:817-823.
168. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26:2529-2536.
169. Ruzyllo W., Tendera M., Ford I., Fox K.M. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007, 67:393-405.
170. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.
171. Fox K., Ford I., Steg P.G., et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009, 30:2337-2345.
172. Swedberg K., Komajda M., Böhm M., et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT). Eur J Heart Fail 2010, 12:75-81.
173. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
174. Peters A., Schoebel F., Jax T., et al. Long-term urokinase therapy and isovolemic hemodilution: a clinical and hemodynamic comparison in patients with refractory angina. Int J Angiol 1999, 8:49.
175. Leschke M., Schoebel F., Stein D., et al. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. J Am Coll Cardiol 1996, 27:575-584.
176. Schoebel F., Leschke M., Jax T., Stein D., Strauer B. Chronic intermittent urokinase therapy in patients with end-stage coronary artery disease sand refractory anginapectoris-apilot study. Clin Cardiol 1996, 19:115-120.
177. Leschke M. Rheology and coronary heart disease. Dtsch Med Wochenschr 2008, 133(suppl 8):S270-S273.
178. Kikuchi Y., Ito K., Ito Y., et al. Double-blind and placebo-conrolled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 2010, 74:589-591.
179. Fukumoto Y., Ito A., Uwatoku T., et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 2006, 17:63-70.
180. Ido A., Hasebe N., Matsuhashi H., Kikuchi K. Coronary sinus occlusion enhances coronary collateral flow and reduces subendocardial ischemia. Am J Physiol Heart Circ Physiol 2001, 280:H1361-H1367.
181. Banai S., Ben Muvhar S., Parikh K.H., et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol 2007, 49:1783-1789.
182. Gallo R., Fefer P., Freeman M., et al. A first-in-man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory angina. Cathet Cardiovasc Intervent 2009, 74:387-394.